Eliminating gender bias in biomedical research requires fair inclusion of pregnant women and gender diverse people.

Autor: Shankar M; Gender and Women's Health Unit, Nossal Institute for Global Health, School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia. mridula.shankar@unimelb.edu.au., Gülmezoglu AM; Concept Foundation, Geneva, Switzerland/Bangkok, Thailand., Vogel JP; Women's, Children's and Adolescents' Health Program, Burnet Institute, Melbourne, VIC, Australia., Goudar SS; Women's and Children's Health Research Unit, KLE Academy of Higher Education and Research, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India., McDougall A; Women's, Children's and Adolescents' Health Program, Burnet Institute, Melbourne, VIC, Australia., Somannavar MS; Women's and Children's Health Research Unit, KLE Academy of Higher Education and Research, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India., Rushwan S; Concept Foundation, Geneva, Switzerland/Bangkok, Thailand., Pujar YV; Women's and Children's Health Research Unit, KLE Academy of Higher Education and Research, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India., Charantimath U; Women's and Children's Health Research Unit, KLE Academy of Higher Education and Research, Jawaharlal Nehru Medical College, Belagavi, Karnataka, India., Ammerdorffer A; Concept Foundation, Geneva, Switzerland/Bangkok, Thailand., Bohren MA; Gender and Women's Health Unit, Nossal Institute for Global Health, School of Population and Global Health, The University of Melbourne, Melbourne, VIC, Australia.
Jazyk: angličtina
Zdroj: Communications medicine [Commun Med (Lond)] 2024 Oct 23; Vol. 4 (1), pp. 211. Date of Electronic Publication: 2024 Oct 23.
DOI: 10.1038/s43856-024-00629-1
Abstrakt: Systematic under-representation of pregnant women and gender diverse pregnant people in clinical research has prevented them from benefitting fairly from biomedical advances. The resulting lack of pharmacological safety and efficacy data leads to medicine discontinuation, sub-optimal dosing, and reliance on repurposed therapies. We identify four roadblocks to fair inclusion. First, investment and research are inhibited by protectionist attitudes among research gatekeepers who view pregnancy as a vulnerable state. Second, exclusion ignores human-specific biological variations affecting medication absorption and impacts on the pregnant body. Third, pregnant populations in low-and middle-income countries face a double disadvantage due to gender and location, despite bearing a disproportionate maternal mortality burden. Fourth, perspectives and experiences of pregnant populations are undervalued in clinical intervention design. We propose five actions to optimize fair inclusion: fostering reciprocal partnerships, prioritizing multi-disciplinary research, awareness-raising of the need for pharmaceutical innovation, conducting regulatory analyses, and promoting responsible inclusion over presumptive exclusion.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: